Remitting-Relapsing Multiple Sclerosis
Conditions
Keywords
multiple sclerosis, relapsing remitting, nonsteroidal anti-inflammatory drug, contrast enhancing lesions
Brief summary
The purpose of this study is to assess the impact of TMP001 in the treatment of patients with relapsing-remitting multiple sclerosis (RRMS). Therefore the average total number of contrast enhancing lesions (CELs) on brain MRI scans at weeks 12, 16, 20, and 24 during treatment with TMP001 is compared to the average total number of CELs on brain MRI scans at week -4 and baseline in these patients . Based on promising preclinical results, the investigators assume a comparable effect of TMP001 on reduction of contrast-enhancing lesions as shown for other immunomodulatory substances in recent clinical studies.
Interventions
DRUGTMP001
600mg TMP001 as gelatine capsules á 200mg taken orally twice per day for a duration of 24 weeks
Sponsors
SocraMetrics GmbH
Dr. Frank Behrens
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
* Age 18 to 55 years * Definite diagnosis of RRMS (according to revised McDonald criteria, Polman et al. 2011, Annals of Neurology 69:292-302) * At least 1 documented relapse during the previous year OR at least 2 documented relapses during the previous 2 years * At least one contrast-enhancing lesion (CEL) on the screening MRI scan at week (-4) * EDSS of 0 - 5 (inclusive) at screening (week -4) * Women of childbearing potential (WOCBP) must use 2 adequate forms of contraception to avoid pregnancy throughout the trial (such as a double barrier method) and for up to 8 weeks after the last dose of TMP001 in such a manner that the risk of pregnancy is minimized * Written informed consent obtained prior to the initiation of any protocol-required procedures * Compliance to study procedure and study protocol
Exclusion criteria
* History of chronic disease of the immune system other than MS or a known immunodeficiency syndrome * Clinically severe active infection (e.g., pneumonia, septicaemia) within the 1 month prior to Screening. * Diagnosis of neuromyelitis optica, clinically isolated syndrome, secondary progressive multiple sclerosis, or primary progressive multiple sclerosis * History of drug or alcohol abuse within 2 years of inclusion to the study * Relapse or corticosteroid treatment within 30 days before screening (week -4) * Interferon-beta, glatiramer acetate, teriflunomide, dimethyl fumarate or fingolimod therapy had to have been stopped 3 or more months before enrolment * Immunosuppressive medication such as azathioprine or methotrexate, Ciclosporin, cyclophosphamide, mycophenolate mofetil, mitoxantrone or cladribine at any time * Any previous therapy with alemtuzumab, ocrelizumab, ofatumumab, rituximab, belimumab, natalizumab, total body irradiation, or bone marrow transplantation * Any investigational drug or placebo within 12 weeks prior to enrolment OR \> 5 half-lives prior to screening (week -4), whichever is longer * Women that are pregnant or currently breast feeding * Concurrent participation in other clinical trials * History of, or current diagnosis of, malignancy (including previously treated skin cancer other than successfully treated basal and squamous skin cancer with no evidence of recurrence within 5 years) * Inability to complete an MRI or contraindications for MRI, including but not limited to claustrophobia, presence of a pacemaker, cochlear implants, ferromagnetic devices or clips, intracranial vascular clips, insulin pumps, or nerve stimulators * Hypersensitivity to contrast agent (Gadolinium, resp. gadopentetate-dimeglumine) * Any reason in the discretion of the investigator regarding the safe participation of the patient in the study or for any other reason, the investigator considers the patient inappropriate for participation in the study. * White blood count (WBC) \<3000 mm3 at screening (week -4)Lymphocytes \< 800 mm3 at screening (week -4)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Comparison of average total number of contrast enhancing lesions | at week -4, week 0 (baseline), week 4, 8, 12, 16, 20 and 24 | Comparison of average total number of contrast enhancing lesions (CELs) on Brain MRI scans at weeks 4, 8, 12, 16, 20 and 24 as compared to the average total number of CELs on brain MRI scans at week -4 and baseline (BL) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Comparison of average total volume of contrast enhancing lesions | at week -4, week 0 (baseline), week 4, 8, 12, 16, 20 and 24 | Average total volume of CELs (in mm3) on brain MRI scans at week 4,8, 12, 16, 20 and 24 as compared to the average total CEL volume on brain MRI scans at week -4 and BL |
| Comparison of T2- hyperintense lesions as assessed in MRI | at week 0 (baseline) and week 24 | New or enlarged T2- hyperintense lesions at week 24 as compared to baseline - Number and Characteristics of T2-hyperintense leasion as to be found in MRI Assessment in Comparison between baseline and week 24 |
| Comparison of T1-hypointense lesions as assessed in MRI | at week 0 (baseline) and week 24 | New T1-hypointense lesions at week 24 as compared to baseline as to be found in MRI Assessment in Comparison between baseline and week 24 |
| relapse rate | week -4 until week 24 | Documentation of any replapse during study period to determine the annualised relapse rate |
| Expanded disability status scale (EDSS) | at week 0 (baseline), week 12 and 24 | EDSS at weeks 12 and 24 as compared to baseline |
| Assessment of Lipid profile at different time points | at week 0 (baseline), week 12 and 24 | Concentration of a variety of lipids will be determined at weeks 12 and 24 and described in comparison to the lipid profile at baseline |
| TMP001-concentrations | week 4, 8, 12, 16, 20 and 24 | Assessment of TMP001-concentrations |
| Pain questionnaire | at week 0 (baseline), week 12 and week 24 | Pain questionnaire at BL, week 12 and week 24 |
Countries
Germany
Outcome results
None listed